Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — ABGSC Oncology Seminar 2021
26 slides from Nykode Therapeutics Asa's conference presentation, November 2021
Slide 1: ABGSC Oncology Seminar
ABGSC Oncology Seminar November 2021
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Multi-target license and collaboration agreement with Regeneron
Nykode Therapeutics enters into multi- target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases Nykode Therapeutics | Corporate Overview | Non-confidential 3
Slide 4: Vaccibody becomes Nykode Therapeutics
Vaccibody becomes Nykode Therapeutics Nykode Therapeutics | Corporate Overview | Non-confidential 4
Slide 5: Overview of Nykode
Overview of Nykode w Leading immune therapy platform allowing rapid development of new drug candidates addressing a broad range of diseases with significant unmet need w Rapidly advancing oncology portfolio, including wholly-owned “off-the-shelf” cancer vaccines against HPV driven cancer types, curr
Slide 6: Regeneron – Nykode Therapeutics collaboration overview
Regeneron – Nykode Therapeutics collaboration overview Discovery, development and commercialization of 5 novel vaccine programs Multi-target license and collaboration Responsible for vaccine generation Responsible for antigen identification, preclinical and clinical development, and characterization
Slide 7: Pipeline
Pipeline Broad oncology coverage and strong partnerships. Leveraging platform within infectious diseases Upcoming Program Indication Discovery/Preclinical Phase 1 Phase 2 Phase 3 Partnerships Milestones Oncology Off the shelf 2H21: Trial Fully VB10.16 HPV16+ cervical cancer3 Enrolled 1H22: Interim D
Slide 8: Regeneron is a partner of choice for Nykode Therapeutics
Regeneron is a partner of choice for Nykode Therapeutics REGENERON OVERVIEW w 10,000+ employees Deep scientific w Scientifically led and focused on innovative expertise and drug development successful track record w Brings unique insights on antigen selection for the collaboration programs w Proven
Slide 9: Perfect fit with Nykode Therapeutics growth strategy
Perfect fit with Nykode Therapeutics growth strategy w Validates our unique therapeutic vaccine platform w Expands and fast tracks our pipeline into novel and innovative areas across oncology and infectious diseases w Fully complementary to current and future pipeline w Cash flow allows us to accele
Slide 10: Flexible Vaccibody platform can fuel multiple, precise products
Flexible Vaccibody platform can fuel multiple, precise products customized for each indication The Vaccibody technology platform APC TARGETED VACCINE PLATFORM APC TARGETED VACCINE PLATFORM is developed based on the concept of targeting antigen to Antigen The Vaccibody platform is agnostic in Present
Slide 11: Vaccibody mechanism of action
Vaccibody mechanism of action The APC targeting vaccine technology platform creates unique rapid, strong and broad immune responses that can be tailored to each disease. MECHANISM OF ACTION Nykode Therapeutics | Corporate Overview | Non-confidential 11
Slide 12: Targeting unit offers unique ability to explore Ag-specific immune tolerance
Targeting unit offers unique ability to explore Ag-specific immune tolerance CANCER AND INFECTIOUS DISEASE AUTOIMMUNITY, ALLERGY ETC Stimulatory Tolerogenic DC DC Natural ligands or scFv binding diverse set of surface receptors IL-12, IFNγ, TNFα, IFNα, IL-6 IL-10, TGFβ, IDO, PD-1, ARG TH 1, TH, 17,
Slide 13: VB10.NEO: Fully individualized neoantigen based cancer vaccine
VB10.NEO: Fully individualized neoantigen based cancer vaccine w Finalized enrollment VB N-01; 5 indications, <50 pt VB10.NEO DATA w Landmark deal with partner of choice Genentech (200m$ upfront & near term, 515m$ additional milestones and low double digit royalties) w Initiated VB N-02, in collabor
Slide 14: VB10.16: Off the shelf therapeutic HPV vaccine
VB10.16: Off the shelf therapeutic HPV vaccine w Finalized Phase I/IIa study with VB10.16 monotherapy in HPV16+ VB10.16 DATA precancerous cervical lesions w Demonstrated ability to induce strong HPV16 specific T cell responses w Strong correlation between vaccine induced T cell responses and lesion
Slide 15: Signifying a new phase of growth and development
Signifying a new phase of growth and development ENCAPSULATES VISION OF FINDING NEW WAYS OF CODING MEDICINES ¨ Draws on our heritage by using the Norwegian words for the words new “ny” and code “kode” ¨ Exploiting future potential building on our core competences ¨ Significantly expanding our pipeli
Slide 16: Strong financial foundation for achieving our vision
Strong financial foundation for achieving our vision w Very strong foundation and solid fundamentals for our business w Total available liquidity of USD188.9 million on September 30, 2021 - Cash and cash equivalents of USD 172,6 million - Liquid money market funds of USD 16.3 million w Financially w
Slide 17: Key investment highlights
Key investment highlights w Unique, leading and proprietary vaccine platform with potential to fuel future pipeline across multiple diseases w Validated through clinical data and collaborations with partners of choice w Solid oncology pipeline addressing broad range of tumor types as well as novel n
Slide 18: Back up
Contact Michael Engsig CEO IR@vaccibody.com BACK UP Nykode Therapeutics | Corporate Overview | Non-confidential
Slide 19: Key strengths of Nykode infectious disease platform
Key strengths of Nykode infectious disease platform w Rapid onset of immunogenicity w Vaccine platform enabling complex and multiple antigen design w Attractive manufacturing, formulation and administration w Tailored to each disease’s correlate of protection w Well-tolerated Nykode Therapeutics | C
Slide 20: Nykode platform has potential to generate leading next generation COVID vaccine
Nykode platform has potential to generate leading next generation COVID vaccine w Increasing evidence that neutralizing w Increasing evidence of the importance antibodies induced by the marketed of broad T cell responses against Focus on Wuhan based vaccines wane over Broad Based COVID-19 Variants o
Slide 21: Adaptive is the partner of choice for T cell based Covid-19 vaccines
Adaptive is the partner of choice for T cell based Covid-19 vaccines Sequenced TCRs and identified Mapped the TCRs to corresponding T Adaptive launched T-Detect™ expanded COVID-19 specific T cell cell epitopes, including cell-based COVID, which is the first-in-class T- clones in more than 6500 sampl
Slide 22: Nykode's SARS-CoV-2 vaccines
Nykode’s SARS-CoV-2 vaccines Nykode is currently advancing two VB10.2129 – RBD CANDIDATE VB10.2210 – T CELL CANDIDATE COVID-19 vaccine candidates with different approaches, and potential to RBD vaccine tailored to the B1.351 (Beta) T-cell epitope vaccine inducing broadly be used in combination VoC t
Slide 23: RBD candidate VB10.2129 induces potent virus neutralization responses across VoC
RBD candidate VB10.2129 induces potent virus neutralization responses across VoC BETA – SOUTH AFRICAN VOC (PSEUDOVIRUS NEUTRALIZATION ASSAY) WUHAN (ORIGINAL STRAIN) ALPHA (UK VOC) GAMMA (BRAZILIAN VOC) w Rapid onset of strong neutralizing antibody responses after a single vaccination Human convalesc
Slide 24: Strong immunogenicity of VB10.2210 in mouse models
Strong immunogenicity of VB10.2210 in 3 mouse models w VB10.2210 induces strong CD8 T cell responses post 1 vaccination against HLA-A2 specific epitopes in humanized HLA-A2 tg mice Tg HLA-A2 BALB/c w The strong T cell responses observed C57BL/6 in two additional mice models show the breadth of the T
Slide 25: VB-D-01 investigating two candidates as a booster
VB-D-01 investigating two candidates as a booster in previously vaccinated subjects w A Phase 1/2, open label, dose VB-D-01 TRIAL DESIGN escalation trial «RBD» CANDIDATE w First subject dosed Nov 3rd Candidate 1: Healthy Cohort 1: Cohort 2: volunteers w Up to 160 subjects are planned DOSE ESCALATION
Slide 26: Thank you
Contact Michael Engsig CEO mengsig@nykode.com +45 6173 1509 THANK YOU Nykode Therapeutics | Corporate Overview | Non-confidential